Zobrazeno 1 - 10
of 9 745
pro vyhledávání: '"ITCH"'
Publikováno v:
Journal of Inflammation Research, Vol Volume 17, Pp 7423-7439 (2024)
Qin-Yu Liu,1,2 Hua-Feng Liu,1,2 Liu-Qing Ye,1,2 Tian Li,1,2 Zuo-Ming Chen,1,2 Yu Wang,1,2 Zhe Peng,1,2 Li Wan1 1Department of Pain Medicine, The State Key Clinical Specialty in Pain Medicine, The Second Affiliated Hospital, Guangzhou Medical Universi
Externí odkaz:
https://doaj.org/article/3e882bd676594d2b94455ae581e05f7e
Autor:
Jeffrey J. Kim, Melissa A. Day
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract The experience of itch and its associated chronic conditions (i.e., atopic dermatitis) form a significant burden of disease. Knowledge of how the brain processes itch, that might occur uniquely for chronic itch populations, could be used to
Externí odkaz:
https://doaj.org/article/9f0d6983db3e47f296720b859957cfad
Publikováno v:
Journal of Inflammation Research, Vol Volume 17, Pp 5957-5975 (2024)
Weixiong Chen,1,2,* Jianqiang Liang,3,* Shuang He,1,4,5 Qingsong Liang,1,4,5 Wenting Tian,6 Aobo Lu,1 Demin Li,1 Zhicheng Huang,1 Guanyi Wu1,4,5 1College of Basic Medicine, Guangxi University of Chinese Medicine, Nanning, Guangxi, 530299, Peo
Externí odkaz:
https://doaj.org/article/9b5fcffcb7524be482f41551b7dfec55
Publikováno v:
JEADV Clinical Practice, Vol 3, Iss 4, Pp 1016-1026 (2024)
Abstract Background Chronic hand dermatitis (CHD) has suboptimal treatments and a negative impact on quality of life (QoL). Topical ruxolitinib, a JAK1/JAK2 inhibitor, is approved for vitiligo and mild‐to‐moderate atopic dermatitis, but has not p
Externí odkaz:
https://doaj.org/article/bf1956e37bb142aa8f82841949665c7b
Autor:
Li-Chi Chen, MD, MPH, Chino Ogbutor, BA, Ümmügülsüm Yıldız-Altay, MD, Kristen J. Kelley, BA, Maryanne M. Senna, MD
Publikováno v:
JAAD Case Reports, Vol 51, Iss , Pp 92-96 (2024)
Externí odkaz:
https://doaj.org/article/4334f636a5fd4246a936cb712c71daf0
Autor:
Gil Yosipovitch, MD, Brian S. Kim, MD, Shawn G. Kwatra, MD, Nicholas K. Mollanazar, MD, Sonja Ständer, MD, Takahiro Satoh, MD, PhD, Pedro Mendes-Bastos, MD, Tsen-Fang Tsai, MD, Elizabeth Laws, PhD, Michael C. Nivens, PhD, Jennifer Maloney, MD, Genming Shi, PhD, Ashish Bansal, MD, MBA, Ariane Dubost-Brama, MD
Publikováno v:
JAAD International, Vol 16, Iss , Pp 163-174 (2024)
Background: Phase 3 PRIME/PRIME2 trials independently demonstrated efficacy and an acceptable safety profile of dupilumab adults with moderate-to-severe prurigo nodularis. Objective: To obtain a more precise estimate of onset and magnitude of treatme
Externí odkaz:
https://doaj.org/article/711afba8cadd4d1c95210d2031b7c4d3
Autor:
Ichiei Narita, Yoshiharu Tsubakihara, Naoko Takahashi, Toshiya Ebata, Takuma Uchiyama, Masaya Marumo, Shota Okamura, Fumitake Gejyo, MR13A9-5 trial investigators
Publikováno v:
Renal Replacement Therapy, Vol 10, Iss 1, Pp 1-13 (2024)
Abstract Background Difelikefalin, a potent and highly selective agonist of kappa opioid receptors, is used to treat moderate-to-severe pruritus in hemodialysis patients. Methods This was a 52-week, open-label phase 3 trial following a 6-week randomi
Externí odkaz:
https://doaj.org/article/6ec72cf3f52340978a4a831b858778f5
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
BackgroundPostherpetic itch (PHI) is an easily overlooked complication of herpes zoster that greatly affects patients' quality of life. Studies have shown that early intervention can reduce the occurrence of itch. The aim of this study was to develop
Externí odkaz:
https://doaj.org/article/1316eb9cf2244137ae7407b3e212d128
More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis
Autor:
Andrew Blauvelt, Kilian Eyerich, Alan D. Irvine, Marjolein de Bruin-Weller, Shawn G. Kwatra, Melinda Gooderham, Brian Kim, Brian M. Calimlim, Wan-Ju Lee, Eliza M. Raymundo, Yingyi Liu, Sarah Ofori, Andrew M. Platt, Jonathan I. Silverberg
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2621-2630 (2024)
Abstract Introduction Atopic dermatitis (AD), with its hallmark symptoms of pruritus and skin lesions, often impairs patients’ quality of life. We assessed time spent with clear/almost clear skin and no/minimal itch during upadacitinib treatment ve
Externí odkaz:
https://doaj.org/article/f20cd55b09a34e87a0a91cfbd7f735cf
Autor:
Gil Yosipovitch, Peter Lio, Franz J. Legat, Raj Chovatiya, Mette Deleuran, Evangeline Pierce, Marta Casillas, Yuxin Ding, Fan E. Yang, Laia Bardolet, Sonja Ständer
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 8, Pp 2171-2180 (2024)
Abstract Background Lebrikizumab demonstrated significant improvement versus placebo for measures of skin clearance and patient-reported outcomes at weeks 16 and 52 in patients with moderate-to-severe atopic dermatitis (AD). We report the sustained i
Externí odkaz:
https://doaj.org/article/7e8540d3df8c409eac7fa642b994ea8b